Table 3.

Cost-effectiveness results for each analysis scenario

Analysis scenario	Incremental cost (£)*, 95% CI, p value	Incremental effect (HbA1c in mmol/mol), 95% CI, p value	ICER†, 95% CI, p value, quadrant	Cost-effectiveness probability for given WTP (%)
				£5000	£10 000	£15 000
Direct healthcare perspective	−2182 to –2783 to −1581, <0.001	−0 to –6 to 6, 0.923	7434, –73369 to 88237, 0.857 dominant	51.2	48.8	48.1
Direct healthcare + patient/carer perspective	−2520 to –3465 to −1576, <0.001	−0 to –6 to 6, 0.923	8585, –91610 to 108781, 0.867 dominant	51.9	49.6	48.3
Sensitivity analysis	−1600 to –2198 to −1002, <0.001	−0 to –6 to 6, 0.923	5451, –57926 to 68828, 0.866, dominant	50.3	48.4	47.6

*Difference in cost between home and hospital management.

†(£ saved per additional unit change in HbA1c (mmol/mol)).

HbA1c, glycated haemoglobin; WTP, willing to pay.